High expression of Enhancer zest homolog 2 (EZH2), a histone 3 methyltransferase, is related to unfavorable outcome to tamoxifen in metastatic breast cancer and is an independent predictor of survival in women with breast cancer [8, 9]. Here, EZH2 is linked to breast cancer.